David J Moss - 19 Apr 2024 Form 4 Insider Report for Inmune Bio, Inc. (INMB)

Role
CFO, Treasurer & Secretary, 10%+ Owner
Signature
/s/ David Moss
Issuer symbol
INMB
Transactions as of
19 Apr 2024
Net transactions value
+$152,246
Form type
4
Filing time
23 Apr 2024, 17:54:56 UTC
Previous filing
20 Mar 2023
Next filing
16 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction INMB Common Stock Award $149,993 +18,028 +1.4% $8.32 1,268,179 19 Apr 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction INMB Common Stock Warrants (right to buy) Award $2,254 +18,028 $0.1250* 18,028 19 Apr 2024 Common Stock 18,028 $9.15 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common shares and warrants reported on this Form 4 were purchased in a registered direct offering at a price of $8.445, for an aggregate purchase price of $152,246.46 pursuant to a securities purchase agreement dated April 19, 2024. The warrants are exercisable immediately upon issuance until the earlier of (i) the two year anniversary of the initial exercise date or (ii) thirty trading days following the reporting of the top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the "Termination Date") but not thereafter, provided however, in the event that the Warrant is held by directors, officers or other affiliates of the Company and the Termination Date is during a period that such officers, directors or affiliates are subject to a blackout with respect to trading in the Company's common stock, such officers, directors or affiliates will have an additional 60 days from the termination of the blackout date to exercise the Warrant.